Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Biogen Idec (NASDAQ:BIIB) climbed $4 to $59.22 on Monday after it announced it expects 2007
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury